Products

New chat. Same project context.

loredev.co AI Models & Agents / Agent Tools & MCP Servers

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Free
No monthly subscription pricing
Creators
Faizan Khan
@tana_shahh· 22 followers
Launched
22d ago
2026-10-25 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
X accounts@tana_shahh
  • Launched on Product HuntLaunch

    Cited recall from local Codex and Claude Code chats

    Oct 25 · 22d agoLaunch page

    At the time: <5K visits/moVisits: next 1 mo +44%

MCP Server & Agent Ecosystem

GitHub · MCP / Skill

Agent, MCP & Developer Integration

MCP ServerAgent Skill
Exposed tool capabilities:
Agent Memory
Browse all MCP Server products →

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct37%
  • Organic Search31%
  • Referrals12%
  • Social7%
  • Other12%

Countries

  • Mexico100%

Search

Domain authority —Domain registered 2026-04-25

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Website does not list public plan prices.

Trial: None · Observed 2026-11-06 · Source page

Pages & changes

Tracked since 2026-10-25

Key pages

Weekly snapshots
Home
loredev.co/ Snapshot 2026-11-06

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Lore get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Lore and what platforms does it support?
Lore is catalogued under Agent Tools & MCP Servers: New chat. Same project context.. Supported platforms: MCP Server.

Related products in this category

AI Models & Agents / Agent Tools & MCP Servers

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.